Napp Launches Mundipharma's Pelmeg In UK
Following launches of Mundipharma’s Pelmeg biosimilar pegfilgrastim in Germany, Ireland and the Netherlands, Napp is now rolling the product out in the UK.
You may also be interested in...
Mundipharma has received a positive opinion from the CHMP for its pegfilgrastim biosimilar. However, the firm would not be drawn on how this version fits into its strategy, given that it already markets its Pelmeg version that it obtained through its acquisition of Cinfa Biotech last year.
Mundipharma is entering into a partnership with Egis for launching its pegfilgrastim biosimilar treatment in Hungary, Romania, Latvia and Lithuania.
As Stada and Gedeon Richter withdraw their applications for a pegfilgrastim biosimilar that the pair have been jointly developing, Mundipharma has pushed ahead with a European roll-out for its Pelmeg version starting in Germany, Ireland and the Netherlands.